Abstract
Chordomas are rare malignancies of bone origin that occur in the axial skeleton, typically the skull base and lumbar/sacral regions. Although often classified as low-grade neoplasms, its locally infiltrative behavior may result in significant morbidity and mortality. Optimal surgical resection may be curative, but up to 50% of the cases relapse within 5 years, and currently there are no systemic treatments approved in this setting. A large proportion of these tumors express stem-cell factor receptor (c-KIT) and platelet-derived growth factor receptors (PDGFRs), providing a rationale for the use of tyrosine-kinase inhibitors (TKIs). A 27-year-old male presented with recurrent chordoma of the lumbar spine 4 years after initial diagnosis. Salvage therapies in the interval included repeat resections and radiation therapy. He ultimately developed multifocal recurrence not amenable to complete excision or reirradiation. A comprehensive genomic profiling assay was performed and revealed nondrugable alterations. Decision was made to proceed with systemic treatment with pazopanib 800 mg/day, resulting in tumor reduction (-23.1% reduction in size) and prolonged disease control. For this patient with a multiple recurrent chordoma and limi...Continue Reading
References
Sep 17, 2004·Cancer·Paolo G CasaliSilvana Pilotti
May 3, 2008·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Michael C HeinrichUNKNOWN Imatinib Target Exploration Consortium Study B2225
Sep 30, 2008·Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc·Gerard J OakleyRaja R Seethala
May 20, 2009·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Suzanne GeorgeMary L Keohan
Jul 3, 2009·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiP G Casali
Oct 23, 2009·Annals of Surgical Oncology·Silvia StacchiottiPiero Picci
Feb 4, 2012·The Lancet Oncology·Brian P WalcottManuel J Ferreira
Feb 15, 2012·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Silvia StacchiottiPaolo Giovanni Casali
Apr 6, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiP G Casali
Jan 25, 2014·Acta Oncologica·T AsklundR Henriksson
Sep 12, 2014·Annals of Oncology : Official Journal of the European Society for Medical Oncology·UNKNOWN ESMO/European Sarcoma Network Working Group
Feb 16, 2015·Critical Reviews in Oncology/hematology·Loïc LebellecNicolas Penel
Jun 23, 2015·Therapeutics and Clinical Risk Management·Salvatore Di MaioRobert C Rostomily
Jul 2, 2015·Cancer Immunology Research·Christopher R HeeryJames L Gulley
Jul 24, 2015·Annals of Oncology : Official Journal of the European Society for Medical Oncology·E BompasN Penel
Oct 24, 2015·Current Reviews in Musculoskeletal Medicine·Xin SunJoseph H Schwab
Jan 7, 2016·Journal of Neuropathology and Experimental Neurology·Arnault Tauziéde-EspariatHoma Adle-Biassette
Nov 9, 2016·Clinical Sarcoma Research·Astrid LipplaaHans Gelderblom
Feb 12, 2017·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiJ Sommer
May 10, 2017·European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)·Loïc LebellecOlivier Mir
Dec 9, 2017·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jeremy S Whelan, Lara E Davis
Jul 1, 2013·Annals of Oncology : Official Journal of the European Society for Medical Oncology·S StacchiottiP G Casali